Monoclonal antibodies specific for interleukin 3-sensitive murine cells by unknown
MONOCLONAL  ANTIBODIES  SPECIFIC  FOR 
INTERLEUKIN  3-SENSITIVE  MURINE  CELLS 
BY  RONALD PALACIOS,  TAURO NERI,  AND  MANFRED BROCKHAUS 
From the Basel Institute for Immunology, CH-4058 Basel, Switzerland 
Interleukin  3  is  a  26-28  kD  glycoprotein  produced  by antigen-  and  lectin- 
stimulated T  lymphocytes, and constitutively released in culture by the mouse 
tumor cell  line  WEHI-3  (i).  Ik-3  was  purified  to  homogeneity from material 
obtained from WEHI-3 cells (2), and the gene encoding it was isolated (3, 4). 
rIL-3 and  IL-3 purified to homogeneity have been shown  (5-7) to promote 
growth of precursors of various lineages of the hematopoietic system. While the 
presence of receptors for IL-3 on the cell membrane of target cells was shown 
by  radioimmunobinding  assay  using  labelled  IL-3  (8),  and  by  the  ability  of 
cytokine-sensitive ceils to absorb IL-3 (9), the biochemical characteristics of such 
receptors and the mechanism of action of IL-3 are not defined. To further- study 
the nature  of the cells sensitive to  IL-3, and  to learn  about the mechanism  of 
action of this growth factor, we have attempted to develop mAb against IL-3-R. 
Here, we describe two mAb, termed CC I 1 and CB5, that appear to react against 
such receptors. 
Materials and Methods 
Animals.  BALB/c, CBA/J, and BALB/c nu/nu mice (5-10-wk-old males and females) 
were purchased  from  the  Institute  for Biomedical Research,  Fiillinsdorf (Fiillinsdorf, 
Switzerland). 
Cells.  The IL-3-dependent lines Ea3.15,  Bc/Bm  11,  CB/Bm7,  Ba/CI,  L/B Ag As, 
10T4-, L/BE~Es,  Ba/Nu, Sj/B, SJ/L, Ba/Bz, NB/W, NZ/S were described elsewhere (9, 
10).  The IL-3-depcndent lines FL/CI, FL]A3, FL/d8 were established from fetal liver 
(BALB/c,  14th day of gestation), and their characteristics will be described elsewhere. 
The  IL-3-sensitive 4c2  myeloid cells  were provided by  Dr. J.  Garland  (University of 
Manchester,  Manchester,  United Kingdom) and the IL-3-dependent 32DC123  myeloid 
line was provided by Dr. J. N. Ihle (Frederick Cancer Research Institute, Frederick, MD). 
The  LBRM-33,  clone  IA5,  IL-t-sensitive T  lymphoma  was  a  gift of Dr. J.  Watson 
(University of Auckland, Auckland,  New Zealand). The P388D1, J771-D4,  NIH-3T3, 
L929, Raw 8.1, and P815 lines were obtained from the American Type Culture Collection 
(Rockville, MD).  EL-4,  70Z/3,  WEHI-279, and A20.2J  lines were provided by Dr.  T. 
Leanderson (Basel Institute for Immunology). BW5147, CTLL, CFL1, and FLH1.25.5 
lines were supplied by Dr. W. Haas (Basel Institute for Immunology). The 18.81 Abelson 
virus-transformed  pre-B  cell  lymphoma  was  supplied  by  Dr.  K.  Marcu  (New  York 
University Medical Center, New York), and the Bcl6 pre-B lymphoma was supplied by 
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Dr. J.  McKearn  (Basel  Institute  for  Immunology).  T  cells  from  BALB/c  mice  were 
obtained by passing spleen cells through nylon wool columns (11), and IgM-bearing spleen 
B lymphocytes were isolated by panning, as described (10).  Cell suspensions from fetal 
liver and bone marrow were prepared as described before (10,  12). Cells from thymuses 
and lymph nodes (mesenteric) were obtained as recommended by Mishell and Shiigi (13). 
Spleen  cells  (2  ×  106  cells/ml)  were  activated  by  Con  A  (2  t~g/ml;  Pharmacia  Fine 
Chemicals, Upssala, Sweden) or LPS (50 #g/ml; Difco Laboratories, Detroit, MI) at 37°C 
for 48 h in 50 ml tissue culture flasks (A/S Nunc, Roskilde, Denmark). 
Cytokines.  rIL-2 (14)  was a  gift of Dr.  W.  Fiefs and  Biogen (Geneva, Switzerland), 
mouse rIL-3 (3) was a gift of Dr. T. Yokota and DNAX (Palo Alto, CA), purified IL-1 
and purified colony stimulating factor of granulocytes and macrophages (GM-CSF)  1 were 
purchased from Genzyme (Suffolk, England).  B cell maturation factor (BMF), constitu- 
tively secreted by the LD1 T  helper line (15) was prepared as follows:  2 X 106 LD1 cells 
in  1 ml of culture medium (Iscove's Dulbecco-modified medium [IDMM] plus 2% heat- 
inactivated human  AB  serum,  gentamycin  (50  t~g]ml),  and  2-ME  (5  x  10  -5  M)  were 
incubated at 37°C for 3-4 d. The supernatants were collected, filtered (0.2 #m Acrodisc 
filters), and assayed for BMF activity as detailed below. Aliquots of active supernatants 
were taken and stored at -20°C. They did not contain detectable IL-1, IL-2, IFN-% or 
B cell growth factor (BCGF) activities. Supernatant from spleen cells (BALB]c and CBA/J 
mice) stimulated with Con A (Con A-Sup) were prepared as described before (15). 
Assays  for Cytokine Activity.  IL-1 was tested by its capacity of promoting the production 
of IL-2 by  LBRM-33,  clone  1A5,  cells  in  the  presence  of PHA  (Wellcome  Research 
Laboratories), as described by Gillis and Mizel (16).  IL-2 and IL-3 were tested for their 
capacity of supporting growth of IL-2-dependent CTL (CTLL) (104 cells/well) and IL-3- 
dependent Bc/Bm I I (104 cells/well) cells as described in detail elsewhere (I 5). BMF was 
assayed as follows:  spleen cells  from BALB/c nu/nu  mice (105 cells/well) suspended in 
microplate wells  (A/S Nunc) in a  final volume of 200 #1 of culture medium containing 
optimal concentrations of LD1 supernatant (final concentration  10-15%) were incubated 
in duplicate at 37°C for 5 d. The number of IgM-secreting cells was determined by the 
protein A reverse hemolytic plaque assay (17). Cell proliferative responses were measured 
by [~H]thymidine uptake (1  #Ci/well,  sp act 5 mCi; Radiochemical Center,  Amersham, 
United Kingdom) during the last 6 h of a 24-h culture period conducted at 37 ° C. 
Mitogen-initiated Proliferation and Antibody Secretion of Spleen Cells.  Spleen cells from 
CBA/J or BALB/c mice (10 s cells/well) suspended in microplate wells in a final volume 
of 200 ul of culture medium were stimulated by Con A  (2 t~g]ml),  PWM (1  ~g/ml), or 
LPS (50 ug/ml) at 37 ° C. Cell proliferation was  3  measured by [ H]thymidine uptake during 
the last 15 h of a 4-d culture period, and the number of IgM-secreting cells was measured 
by the protein A plaque assay after 5 d of culture. 
Development of CCll and CB5 mAb.  The IL-3-R  + Ea3 cells (10) were injected (2 x  107) 
i.p. into a BALB/c mouse, and this procedure repeated twice at intervals of 3 wk between 
each injection. 4 d after the last boost, splenocytes were isolated and fused with the HAT- 
sensitive non-Ig secretor myeloma PAI-O (a gift of Dr. H. Jacot, Hoffmann-La Roche, 
Basel, Switzerland) at a ratio of 5:1  using a 50% (wt/vol) solution of PEG (4,000 tool wt). 
The cells were distributed in 96  microplate wells  in a  final volume of 200  ~1 of HAT 
selective medium. 10-15 d later, wells containing growing hybridomas were screened for 
reactivity against  IL-3-sensitive clones  by an  indirect  radioimmunobinding assay using 
1~SI-labelled F(ab)2  rabbit anti-total  mouse  Ig (New  England  Nuclear,  Boston,  MA) as 
second antibody.  5 out of 1,340  wells  screened were found to specifically react against 
IL-3-sensitive cells. Two of these five hybridomas are described here; hybridomas CC11 
and CB5 were cloned and recloned by limiting dilution,  (0.5 cells/microplate well) and 
are maintained in  culture  medium in  tissue culture  flasks.  The type of Ig secreted by 
CC11 and CB5 hybridomas was identified by double-diffusing agar gels using goat anti- 
mouse IgG1, IgG2, IgG3, and IgM antisera (Nordic, Tilburg, the Netherlands).  CC11 
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and  CB5  hybridomas  secrete  mouse  IgG2,  which  bind  to  protein  A,  and  fix  rabbit 
complement. CCI 1 and CB5 mAb were purified from  hybridoma culture supernatants 
by protein A-Sepharose column chromatography (Pharmacia Fine Chemicals). They were 
dialyzed, filtered, and stored at -70°C until used. 
Other Antibodies.  The following mAb were used  in  the  form of hybridoma culture 
supernatants: M 1/42 (18) antibody reactive with It-2 antigens of all haplotypes; 34-2-12 
S (I 9) antibody against H-2-D  d. Both hybridomas were obtained from the American Type 
Culture Collection.  14.8  (20) antibody against the B-220 molecule was kindly provided 
by Dr. P. Kincade (Oklahoma Medical Center, OK). 
Purification  of CCll/CB5 + and CCtl/CB5-  Bone  Marrow Cells.  Bone  marrow celt 
suspensions were prepared from femurs and tibia of BALB/c mice as detailed elsewhere 
(12).  The cells were washed two times in balanced salt solution (BSS) and resuspended in 
separation medium (IDMM with 5% FCS, gentamycin, and 2-ME) at 6  X  107 cells in 3 
ml.  The cells (3  ml of cell  suspension) in  50  ml conical plastic tubes (2070  F;  Falcon 
Labware, Oxnard, CA) were exposed to CC11  or CB5 mAb (70 ug/tube) at 4°C for 30 
rain.  The tubes were centrifuged (5  rain, 800 g), and the supernatants were discarded. 
The cells in the pellet were resuspended by gently shaking the tubes, and they were mixed 
with a  suspension of protein A-coupled SRBC (final dilution  1:25) in a final volume of 
5-6 m l of separation medium. The tubes were spun (5 rain, 800 g), and incubated at 4 °C 
for 45-60  min. The pellet was gently resuspended with wide-bore Pasteur pipettes and 
layered  over a  3-ml  Ficoll-Hypaque gradient  contained  in  round-bottom  plastic tubes 
(2057; Falcon Labware), and the tubes were centrifuged at 4°C (40 rain, 1,100 g). Non- 
rosette forming cells were collected from the interphase, and rosette-forming cells in the 
pellet were resuspended gently in separation medium and centrifuged again over Ficoll- 
Hypaque gradients as indicated above. Rosette-forming cells in the pellet of the second 
gradient were collected, the erythrocytes were iysed with ammonium chloride-Tris buffer, 
and the  remaining viable cells were washed in  separation medium and resuspended  in 
culture  medium (see above) at desired  concentrations.  The non-rosette  forming cells 
obtained in the first gradient were treated with CCI 1 or CB5 mAb (40 ~g/ml, depending 
on which antibody was used in the separation) plus low-toxicity rabbit complement (final 
dilution,  1:12;  Cedarlane Laboratories) to further deplete these cells of CC11/CB5 + cells. 
The cells were washed and  resuspended  in  culture medium at desired  concentrations. 
Both populations were then cultured at 37°C for 12-18 h to allow both shedding of the 
antibodies and reexpression of the CC1 I/CB5 glycoprotein. 
Purity  of the  cell  populations  was  determined  by  immunofluorescence microscopy 
(200-300  cells analyzed) using both CC11  and CB5  mAb as first antibody, and FITC- 
conjugated  F(ab')2  rabbit  anti-mouse  IgG antibody as  second  antibody.  Non-rosette 
forming cells  contained  ~<1-4%  CC11/CB5 ÷ cells,  and  rosette-forming cells  had  96- 
98.7%  CC11/CB5 ÷ cells.  The  experiment described  in  Fig.  5  was  conducted  with  a 
preparation of cells where we could obtain highly purified CC11 + (I>98.7%  CC11/CB5 ÷ 
cells) and CC 11- (~< 1% CC 11/CB5 + ceils) cell populations. CC 11/CB5 + and CC 11/CB5- 
cells (5 ×  104 cells/well) were placed in round-bottom microplate wells in the presence or 
absence of the  following stimuli: purified  IL-1  (20  U/ml), rIL-2 (20  U/ml),  rlL-3  (20 
U/ml), or Con A-Sup (final concentration  25%) in a  final volume of 200 ul of cultur~ 
medium  per  well.  The  cultures  in  triplicate  were  incubated  at  37°C  for  48  h.  Cell 
proliferation was determined by [3H]thymidine uptake (1/~Ci/well) during the last 8 h of 
the culture period. 
Immunofluorescence Staining and Flow Fluorometry.  The different types of cells (3-5 x 
10s), harvested in logarithmic phase of growth, were incubated with purified CCI 1 and 
CB5 mAb (15 ug/tube), or with the M1/42 rat anti-H-2 antigen antibody (positive control) 
at 4 °C for 30 min. The cells were washed once and resuspended in buffer (PBS plus 0.1% 
BSA plus  0.1%  NaNs)  containing an  appropriate dilution  of FITC-conjugated  F(ab')~ 
rabbit anti-mouse IgG or rabbit anti-rat IgG at 4°C for 30 rain. Negative controls were 
cells incubated in second labelled antibody only. The cells were washed twice in buffer, 
and a third time in buffer containing propidium iodine to exclude dead cells from anaTysis. 
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Systems, Mountain View, CA) equipped with an argon ion laser. Data were collected from 
104 ceils analyzed in 1024 channels using logarithmic amplification of fluorescence emitted 
by single viable cells. 
Effect of CC11 and CB5 mAb on Various Cellular  Functions.  The effects of CC11  and 
CB5  mAb on the action of IL-1  (20 U/ml), IL-2 (20  U/ml), IL-3 (1-100  U/ml), BMF 
(final concentrations 10-40%); proliferative responses to Con A, PWM, and LPS; and on 
maturation of spleen B cells into antibody-secreting cells driven by LPS were studied by 
adding different concentrations of CC 11  and CB5 mAb (0.1-40 #g/ml) or control mAb 
M 1/42,  14.8 (final concentrations 10-40%) at the beginning of the assays, carried out in 
triplicate as detailed above. 
The capacity of IL-3 of modulating the expression of the CC11/CB5 glycoprotein on 
the  cell  membrane  was  studied  as  follows:  Bc/Bm  11  IL-3-sensitive  cloned  cells  in 
logarithmic phase of growth were incubated (2.5 ×  105 cells in 12 × 75-mm round-bottom 
plastic tube [2054; Falcon Labware]) in the presence or absence of 150 U of IL-3, IL-2, 
or GM-CSF at 37°C for 6-8 h. The tubes were centrifuged (5 min, 800g), the supernatants 
were discarded, and the cells were tested for the presence of CC 11, CB5, and class I MHC 
antigens (control) by immunofluorescence staining and flow cytometry as detailed above. 
Cell Labelling and lmmunoprecipitation.  Ceils (2 ×  107, viability >90%) were extensively 
washed with PBS,  1 mM CaC12, and suspended in 0.4 ml of the same buffer with 0.1  ml 
200  mM  sodium  phosphate,  pH  7.2,  in  a  tube  coated  with  100  #g  Iodogen  (Pierce 
Chemical Co., Rockford, IL). After addition of 1 mCi carrier-free Nal~I (100 mCi/ml; 
Amersham Corp.) the tube was shaken gently for 15 min on ice. The cells were pelleted 
at 3,000 g for 10 s, and washed three times with 1 ml cold PBS,  1 mM CaCI2. The pellet 
was  lysed  in  1  ml  lysis  buffer,  pH  7.2,  containing  1%  NP-40  (Fluka  Biochemicals, 
Switzerland),  0.1%  sodium  deoxycholate,  20  mM  sodium  phosphate,  0.14  M  sodium 
chloride,  1 mM PMSF, 0.3 TIU/ml aprotinin (Sigma Chemical Co., St.  Louis, MO) and 
0.05% Ovalbumin. After standing for 3 rain at 0°C, the lysate was spun 3 min at 12,000 
g, and the supernatant was further cleared at 50,000 g for 1 h. 
Antibody was coupled to CNBr-activated Sepharose 4  B (Pharmacia Fine Chemicals) 
according to the manufacturers recommendations. In a  typical experiment, 25 tA anti- 
body-Sepharose beads were incubated with 0.5 ml lysate in a vial, rolling over end for 1 
h at 4 °C. The beads were washed, with change of tubes, once with 1 ml and four times 
with 5 ml lysis buffer without the protease inhibitors. The final wash was with 3 ml of 20 
mM Tris-HCI, pH 8.0. 
Electrophoresis and Enzyme  Treatment.  Antigen was eluted from the Sepharose beads 
with  1% SDS sample buffer containing either  1% 2-ME or 4 mg/ml iodoacetamide, and 
boiled 3 min before SDS-PAGE. Two-dimensional electrophoresis was performed accord- 
ing to the procedure of O'Farrell (21), after eluting the antigen with 9 M urea, 1% 2-ME, 
2% ampholines, pI 9-11  (LKB, Br~mma, Sweden), and 2% NP-40. For treatment with 
endoglycosidase F, the beads were boiled 3 min in 50 ~1 sample buffer containing 0.5% 
SDS,  1% 2-ME, 10 mM sodium EDTA, 10 mM Tris-HC1, pH 8.8.5 t~l 10% NP-40 and 5 
#1 endoglycosidase F (kindly supplied by Dr. J. Kaufman, Basel Institute for Immunology) 
with  1 mM  PMSF and 0.3  TIU/ml aprotinin were added and incubated  3 h  at  37°C. 
Under these conditions, the proteolysis observed with 12~I-BSA  as substrate was negligible. 
15 ~1 of a solution containing  10% SDS,  40% 2-ME, and 50% glycerol were added, and 
the samples were boiled again befbre SDS-PAGE. [14C]Methylated proteins (Amersham 
Corp.) were used as molecular weight markers. 
Results 
The hybridomas CC11  and CB5  were obtained by fusing splenocytes from a 
BALB/c  mouse (repeatedly immunized with  IL-3R  ÷ Ea3  cells) with  the  HAT- 
sensitive  myeloma  PAI-O.  Both  CCll  and  CB5  hybridomas  secrete  mouse 
IgG2bK,  which  bind  to  protein  A  and  which  fix  rabbit  complement.  All  the 
experiments  described  below  were  carried  out  with  purified  CC11  and  CB5 
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Specificity.  The specificity of CC 11 and CB5 mAb was defined by testing their 
reactivity against a  large panel of normal cells, growth factor-dependent lines 
and  tumor  cells  representing  various  lineages  by  both  immunofluorescence 
staining and flow fluorometry and indirect radioimmunobinding assays.  All  18 
IL-3-dependent mouse cell lines derived from spleen, bone marrow, and fetal 
liver tested, the pre-B cell lymphomas (70Z/3,  18.81,  Raw 8.1) studied and the 
mastocytoma P-815 carried both CC 11 and CB5 antigens on their cell membrane. 
The following type of cells were negative for CC 11 and CB5 antigens: thymomas 
(EL-4, BW5147), IL-2-dependent T cell lines (CTLL, CFL 1), the cytolytic T  cell 
hybrid FLH  1.25.5,  IL-l-sensitive LBRM-33 (clone 1A5) T  lymphoma, macro- 
phage  tumor  cells  (P388D1,  J771-D4,  WEHI-3),  surface  Ig  +  B  lymphomas 
(BCL1,  WEHI-279,  A20.2J),  fibroblast  cell  lines  (NIH3T3,  L929),  purified 
spleen T  cells, Con A-activated splenocytes, an enriched population of normal 
IgM  ÷ B  lymphocytes from spleen, and  LPS-activated splenocytes. In all  cases, 
cells that had the CC11  antigen were also positive for the CB5 antigen, and the 
reverse, CB5- cells did not express CC11  antigen. Fig.  1 shows some examples 
to illustrate these results. 
Tissue  Distribution.  We  studied  the  presence of CCll + and  CB5 ÷ cells  in 
various tissues  from normal  mice by immunofluorescence staining and  either 
microscopy or flow cytometry analysis. ~47-53%  (n =  3) nucleated cells from 
fetal liver (14th day of gestation) of BALB/c mice, 61-79%  (n =  7) nucleated 
bone marrow cells from 6-8-wk-old (CBA/J, BALB/c) mice, but only 3-10% (n 
=  3) splenocytes from young adult BALB/c mice were positive for both CC11 
and CB5  antigens. Thymus, lymph node, heart, and kidney from young adult 
mice were negative (~< 1%). 
Biochemical  Characterization.  The CC11  mAb precipitates from surface 125I- 
labelled 1L-3-dependent clones a  protein that runs as a  very diffuse band with 
an Mr of 50,000-70,000  under reducing conditions as determined by SDS-PAGE 
(Fig.  2a,  lane A).  Depending upon exposure time, the band resolved into two 
diffuse species (Fig. 2b, lane A), which were also present in the alkylated sample 
under nonreducing conditions (not shown). CC 11 mAb did not precipitate similar 
species from radioactively labelled control EL-4 cells (Fig. 2a, lane F and b, lane 
E). The 75,000 Mr band present in precipitates from EL-4 ceils with CC11  mAb 
was not observed in all  the experiments. In the instances where it was present 
(such as in the experiment depicted in Fig. 2) the band showed a very different 
mobility before and after deglycosylation, and had a different pI than the antigen 
precipitated from both IL-3-dependent clones and freshly isolated bone marrow 
cells (Fig.  2, a and b, and other data not shown). Furthermore, in immunopre- 
cipitations from the same labelled EL-4 cells with mAb of different specificity 
than that of CC11/CB5  mAb, a similar 75,000 Mr band was observed again in 
some but not all  the experiments. Thus, it was not specifically precipitated by 
CC 11 and CB5. Rather, it coprecipitated nonspecifically from labelled EL-4 cells 
under the conditions studied. Accordingly, the CC11/CB5 glycoprotein was not 
detected (four separate experiments) on the cell membrane of the same EL-4 
cells, as determined by immunofluorescence and flow fluorometry analysis (Fig. 
1, i). 
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FIGURE  1.  Specificity of mAb CC11 and CB5 for mouse IL-3-sensitive cells. The specificity 
of the CC 11 and CB5 was determined by studying their reactivity against a large panel of cells 
representing several  lineages  and obtained  from different  tissues by immunofluorescence 
staining and flow fluorometry. Some fluorescence  histograms  generated in these studies are 
only shown here to illustrate  the results obtained.  They are:  (A) Ea3.15  IL-3-sensitive clone 
(BALB/c); (B) CB/Bm7 IL-3-sensitive B stem cell (CBA/J); (C) Bc/Bm 11 IL-3-sensitive B stem 
cell (BALB/c); (D) 4C2 IL-3-sensitive myeloid line (BALB/c); (E) freshly isolated nucleated 
cells from fetal  liver (BALB/c 14th day of gestation);  (F)  10T4- 1L-3-sensitive pre-B cells 
(B10T.GR);  (G) 32 dcl IL-3-sensitive myeloid cells (C3H/Hej); (/4) L/B AgA2 IL-3-sensitive B 
stem cell (MRL/lpr); (I) EL-4 thymoma; (J) P388D1 macrophage; (K) WEHI-279 B lymphoma; 
(L) L929 fibroblast  cells; (M) LBRM-33, clone 1A5, IL-l-sensitive  T  lymphoma;  (N) CTLL 
I L-2-sensitive T cells; (O) Raw 8.1 pre-B lymphoma; (P) 18.81 pre-B lymphoma. 
that M1/42  anti-H-2  precipitated  from IL-3-dependent Bc/Bm  11  cells proteins 
with Mr compatible with that of H-2 antigens, but incompatible with that detected 
by CC11  or CB5 (data not shown). 
The  CC 1 1  molecules  from  different  cell  populations  show  slightly  different 
mobilities  in  SDS-PAGE,  depending  on  the  origin  of the  cells  (Fig.  2a).  Thus, 
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FIGURE 2.  (a) SDS-PAGE analysis  of immunoprecipitated material with mAb CC11  from 
surface ~2~l-labelled  cells. The lysate was adjusted to the same specific activity before precipi- 
tation. Lanes: A, Bc/Bm  11  cells; B and C, two different preparations of bone marrow cells; 
D,  Raw8.1  cells; E, Bcl6 cells; F, EL-4 cells. (b) SDS-PAGE analysis of immunoprecipitated 
material with mAb CCI 1 before and after treatment with endoglycosidase F. Lanes: A and B, 
Bc/Bm 11 cells; C and D, bone marrow cells (BALB]c); E and F, control EL-4 cells. (c) and (d) 
Two-dimensional electrophoresis (IEF followed by SDS-PAGE) of CC11  antigen precipitated 
from Bc/Bm  11  cells (c) and bone marrow cells (BALB/c) (d).  Numbers to the left in each 
section are Mr (x 10  -3) markers. 
lower  mobility than  the  CC11  protein  of IL-3-dependent  clones (Fig.  2a,  lane 
C). Likewise, the CC 11  molecule of Abeison virus-transformed  pre-B lymphomas 
(Raw8. I, Bc-! 6) has similar mobilities to that of IL-3-dependent  clones and bone 
marrow  cells, but the  lower Mr species of the  molecule are not present in  these 
cells (Fig.  2a,  lanes D  and E).  Such  heterogeneity  in size of the CC11  molecule 
seems to be due mainly to differences in glycosylation. Indeed, treatment  of the 
CCI I  antigen  of either  IL-3-dependent  Bc/Bm  11  cells or  bone  marrow  cells 376  MOUSE INTERLEUKIN 3  RECEPTORS 
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FICURE 3.  CC11  and CB5 inhibit lL-3-driven  growth ofcytokine-dependent clones. Bc/Bm 
1  ] cloned  cells were incubated in microplate wells in the presence ofCCl I (©), CB5 (O), (2.0 
ug/ml), control antibodies M1/42 (ZX), 14.8 (m) (final concentration 30% vol/vol) or medium 
only at 22°C for 10 min. Different concentrations of rIL-3 were added to the cultures in a 
final volume of 200 •l/well.  Cell proliferation was measured by [SH]thymidine  uptake during 
the last 6 h of the culture period. The results are expressed as percent inhibition of IL-3- 
driven proliferation, and were calculated as: percent inhibition =  1 -  (cpm from cultures 
established with mAb) x 100/(cpm from cultures established without mAb). 
with endoglycosidase F  yields a  band of M, ~40,000,  and a  doublet at 30,000 
and  28,000  on  both  types of cells, probably representing partially and totally 
deglycosylated material, respectively (Fig. 2b, lanes B and D). Two-dimensional 
electrophoresis  shows that the CC11  antigen of either IL-3-dependent Bc/Bm 
11  cells (Fig.  2c) or bone  marrow cells (Fig.  2d)  focuses between pH  5.7 and 
6.2,  which is accompanied by four weak bands at a  lower molecular weight of 
pH 7.0-8.0, probably reflecting different degrees of sialylation. 
The  molecules  recognized  by  CCll  and  CB5  are  identical  by  SDS-PAGE 
analysis on all cells tested. 
Functional Relationship to the Action of lL-3.  The possible functional relation- 
ship between the CC 11/CB5 glycoprotein and the action of I L-3 was investigated 
in three different ways. First, we tested the effect of mAb CC 11 and CB5 on the 
growth of cloned cell lines supported by IL-3. CC 11  inhibited the proliferative 
response promoted by IL-3.2 #g/ml of the antibody inhibited by -60-70%  the 
proliferation of Bc/Bm  11  cells supported  by  10  U/ml  of rIL-3 (Fig.  3).  This 
inhibitory effect was greater if lower concentrations were  used, and could be 
overcome  by  higher  concentrations  of the  growth  factor  (Fig.  3).  mAb  CB5 
exbibited less inhibitory activity than CC11  (Fig. 3 and Table I). The antibodies 
interfered with the action of IL-3 on different IL-3-sensitive cell lines obtained 
from various tissues (fetal liver, bone marrow, spleen) and derived from different 
strains of mice. The inhibition of IL-3-driven growth caused by mAb CC11 and 
CB5 is specific, mAb against other antigens present on the cell membrane of the 
same target cells (eg. H-2, B-220) did not affect their growth supported by IL-3 
(Fig.  3).  Moreover,  neither  CC11  nor  CB5  showed  inhibitory or  stimulatory 
effects on the action of IL-2, purified IL-1, or B cell maturation factor (BMF); 
nor on the proliferative responses of splenocytes initiated by Con A, PWM, and 
LPS;  nor  on  the  maturation  of spleen  B  cells  into  antibody-secreting  cells 
stimulated  by  LPS  (Table  I).  Finally,  CC11  and  CB5  do  not  by  themselves 
support  growth  of IL-3-dependent  cells,  either  in  soluble  form  or  linked  to 
Sepharose beads (R. Palacios, unpublished results). 
Second, we tested whether IL-3 would modulate the glycoprotein recognized PALACIOS ET  AL. 
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Biological Activity 
LPS  mAb 
BMF (IgM  Con A  PWM  IL-1  IL-2  1L-3  PFC/culture)  IgM 
Acpm  PFC/culture 
gg/ml  Acpm  Acpm 
None  19,721  23,737  20,107  8,400  199,250  136,817  74,509  13,500 
CCll 
2.0  18,896  23,210  9,776  8,550  201,073  143,021  79,533  12,400 
10.0  19,630  23,201  4,091  8,800  214,333  138,163  78,451  13,200 
20.0  19,513  23,144  1,025  8,120  207,824  144,712  81,198  12,100 
CB5 
2.0  I9,710  23,112  15,695  8,080  217,772  130,578  73,128  15,040 
10.0  18,818  23.,635  10,187  7,950  206,263  141,126  76,066  12,500 
20.0  19,601  23,025  4,351  8,600  218,503  138,025  71,186  13,600 
CC11 and CB5 mAb were tested  for their activity on the action of purified IL-1 (20 U/ml), rIL-2 
(20 U/ml), rlL-3 (10 U/ml), BMF (final concentration,  10%); proliferative responses  of spleen cells 
to Con A (2 ug/ml), PWM (1  #g/ml), LPS (50 #g/rnl);  and in the maturation of splenic B cells into 
antibody-secreting cells stimulated  by LPS. Data are expressed  as Acpm (cpm in stimulated  cultures 
-  cpm unstimulated  cultures)  for the proliferative responses,  and as IgM  PFC per culture for the 
antibody-production responses. 
by CC11  and CB5.  The IL-3-dependent Bc/Bm  11  cells  were preincubated in 
rIL-3  at  37°C  for 6-8  h.  The same cells were also preincubated in rIL-2 or 
purified GM-CSF and served as controls. The cells  were then assessed for the 
presence of CB5, CC11, and class I MHC (control) antigens by immunofluores- 
cence staining and flow cytometry. The results (Fig. 4) showed that Bc/Bm 1 I 
cells preincubated in IL-3 bound significantly less CC11 and CB5 than the cells 
preincubated in medium only (Fig. 4, a and b). IL-3 did not, however, affect the 
expression of class I MHC antigens on the cells (Fig. 4 b). Nor did GM-CSF (Fig. 
4 c) or I L-2 (Fig. 4 d) modulate the expression of the CC 11/CB5 glycoprotein on 
the  cells.  Thus,  IL-3  specifically modulates the  expression  of the  CC11/CB5 
glycoprotein on the cell membrane. 
Third,  freshly isolated bone  marrow cells  were  separated  into cells  having 
(CC 11 +) and cells lacking (CC 11-) the CC 11 glycoprotein on their cell membrane, 
as detailed in  Materials and Methods. After an incubation period at  37°C  to 
allow both shedding of the antibody and reexpression of the CC11/CB5 glyco- 
protein, CC11 ÷ and CC11- cell populations were tested for their proliferative 
response  to  IL-3  and  to  other  cytokines as  well.  The  results,  obtained in an 
experiment where we could obtain highly purified CC11 + (>~98.7% CC11/CB5  + 
cells) and CC 11- (~< 1% CC 11/CB5  ÷ cells) cell populations are depicted in Fig. 5. 
While CC 11 + cells proliferated in response to IL-3 CC 11- cells did not. Neither 
cell population showed significant responses to purified IL-1 or rIL-2, but both 
CC 11 + and CC 11- cells proliferated in response to a crude supernatant contain- 
ing various activities released by mouse spleen cells stimulated by Con A (ConA- 
Sup). Similar results were obtained when bone marrow cells were separated into 378  MOUSE  INTERLEUKIN  3  RECEPTORS 
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FIGURE 4.  rlL-3 modulates the expression of the CCI I/CB5 glycoprotein in the cell mem- 
brane. Bc/Bm  11  cells were preincubated in medium only (A), IL-3 (B), GM/CSF (C), or IL-2 
(D) at 37°C  for 8  h.  The  cells were then tested for the presence of CC11,  CBS, and class I 
MHC antigens by immunofluorescence  staining and flow cytometry. Histograms from cells of 
the different groups incubated with second labelled antibody only (controls). 
Cells  Stimulus  (3H) thymidine  uptake  (cpm  x10-3) 
4  12  20  28 
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FIGURE 5-  Bone  marrow cells were separated  into CC11 + and CC11-  cell populations and 
tested for their proliferative response  to the agents  indicated (final concentration  of IL,  20 
U/ml;  Con  A-Sup  final  concentration,  25%).  Cell  proliferation  was  determined  by  [3H]- 
thymidine uptake during the last 8  h of a  2-d culture period conducted at 37°C.  The results 
are expressed as cpm  ×  10-  (mean  of triplicate samples).  The  SEM  in this experiment was 
<8.3%. 
CB5 + and CB5- populations and with bone marrow cells from mice carrying the 
xid  and  nude  mutations,  which  preclude  development  of  mature  T  and  B 
lymphocytes (22,  23) (data not shown). Thus, bone marrow cells that have  the 
CC 11/CB5 molecule on their cell membrane are sensitive to IL-3, whereas bone PALACIOS  ET  AL.  379 
marrow  cells  that  do  not  express  this  molecule  on  the  cell  membrane  are 
insensitive to IL-3. 
Discussion 
Evidence was presented  in Results that  strongly supports the view that  mAb 
CC11  and CB5 may react against receptors for mouse IL-3. CC11  and CB5 (a) 
specifically inhibited the action of IL-3 on growth factor-dependent clones. (b) 
IL-3 specifically modulated the glycoprotein detected by mAb CC11  and CB5 
on the cell membrane.  (c) The  CC11/CB5 glycoprotein is present on all  IL-3- 
sensitive cell lines tested, but not on cells insensitive to IL-3. (d) CC11 ÷ and CB5  + 
cells are  well  represented  in  tissues  known  to contain  IL-3-sensitive cells (eg. 
bone  marrow,  fetal  liver),  but  not  in  tissues  where  the  majority  of cells  are 
insensitive  to  IL-3  (e.g.  adult thymus,  lymph node,  heart,  kidney). (e)  Freshly 
isolated  bone marrow  cells that  have  the  CC11/CB5  glycoprotein on  the  cell 
membrane are sensitive to IL-3, while bone marrow cells that lack this molecule 
are not. 
The  alternative  explanation  for the  observations described here  is  that  the 
CC11/CB5 glycoprotein might not be the IL-3R per se, but it might be related 
to it.  Although  we cannot  directly  exclude  this  possibility,  it  seems to  us less 
likely because one needs to  further  imply  that  the  CC11/CB5  glycoprotein is 
linked to IL-3-R on the cell membrane (to explain its specific modulation by IL- 
3), and that  it plays specifically a  crucial  role in the action of IL-3.  We expect 
that,  by isolating  the  gene  encoding  the  CCll/CB5  glycoprotein,  and  using 
subsequent  gene  transfer  experiments,  we will  be able  to directly  distinguish 
between these possibilities. In any event, it is clear that the CC 11 and CB5 mAb 
specifically react against  IL-3-sensitive normal  mouse cells, and  that  the glyco- 
protein detected by them plays an essential role in the action of IL-3. 
The CC11/CB5 molecule has an Mr of 50,000-70,000  by SDS-PAGE, and a 
pI of 5.7-6.2. The same species were observed under reducing and nonreducing 
conditions,  excluding  the  presence  o£ disulfide  links  between them.  There  is 
heterogeneity in size of the CC 11/CB5 glycoprotein expressed on I L-3-depend- 
ent clones, bone marrow cells, and pre-B cell lymphomas. This is due mainly to 
differences in glycosylation. Treatment  of the CC 11/CB5 molecule with endo- 
glycosidase  F  yields  bands  of Mr  40,000,  30,000,  and  28,000  from  material 
obtained from both IL-3-dependent clones and bone marrow cells. The different 
species probably represent  partially  and  totally deaminoglycosylated material, 
respectively, or alternatively,  might  indicate the presence of two proteins.  The 
data are most compatible with the view that the CC 11/CB5 molecule is made of 
a single chain protein of 28,000 Mr, carrying heterogeneous N-linked glycans of 
high relative molecular weight.  Nevertheless, at present we cannot exclude the 
possibility that  this  molecule  is  made  of two chain  proteins  of different  size. 
Further biochemical studies will hopefully distinguish between these possibilities. 
The  heterogeneity  in  size  of  the  CCll/CB5  glycoprotein  of  different  cell 
populations is not a  unique feature of this molecule.  It is known that the same 
polypeptide  can  be  glycosylated  differently  in  different  cell  types  (24).  For 
example, receptors for several iigands (eg. C3, Fc, IL-2) have been found (25- 
27) to exhibit heterogeneity due mainly to differences in glycosylation. 380  MOUSE INTERLEUKIN 3  RECEPTORS 
Interestingly,  pre-B  cell  lymphomas  (18.81,  Raw  8.1,  Bcl6)  express  the 
CC 11/CB5 glycoprotein on their cell membrane. These results, and the findings 
that purified  CC11/CB5 + bone marrow cells contain  B cell precursors (surface 
Ig-negative)  that  proliferate  and  give rise  in  vitro  to  antibody-secreting  cells 
after LPS stimulation (R. Palacios, manuscript in preparation) are consistent with 
the proposition that IL-3 acts on a population of mouse B cell precursors (9,  10). 
Studies are in progress to determine whether bone marrow cells committed to 
the T  cell lineage express the CC11/CB5 glycoprotein.  Thymocytes from fetal 
and  adult  thymuses have neither  detectable CCI 1/CB5  antigens,  nor do they 
use IL-3 as growth factor (R. Palacios unpublished results). 
Freshly isolated nucleated cells from fetal  liver and  bone marrow  cells have 
CC11/CB5  antigen,  and  proliferate  in  response  to  IL-3,  suggesting that  these 
cells may be using IL-3 in vivo. Mature T  cells are known to synthesize IL3 (28), 
but these  cells are  not present  in  fetal  liver,  nor  are  they easily detectable in 
young adult T  cell-deficient nu/nu mice. Yet these mice have normal  (in  bone 
marrow) and increased (in spleen) numbers of CC11/CB5 + cells as compared to 
euthymic  mice,  and  both  tissues contain  cells that  grow  in  IL-3  (R.  Palacios, 
unpublished results). These observations raise the question what cells normally 
make IL-3 in fetal liver and bone marrow. 
Finally, it is worth stressing that the CC11/CB5 glycoprotein is expressed not 
only on normal cells but also on their tumor counterparts. There is accumulating 
evidence that  some oncogenes code for molecules resembling  growth  factors, 
their receptors, or molecules involved in the transduction of signals delivered by 
growth  factors (29,  30).  Possibly the  CC11/CB5  protein  is encoded by a  pro- 
tooncogene involved in transformation of haematopoietic ceils. Our initial survey 
excluded the products of the src, ras,  abl, erb-B, mos, sis, fes, Myc, Myb, fos, and 
fms as candidates, based on biochemical criteria and cellular location. 
Summary 
The  mAb  CCll  and  CB5  reacted  against  all  18  IL-3-dependent  cell  lines 
tested, but not against cells insensitive to IL-3. Up to 53% nucleated cells from 
fetal  liver (14th  day of gestation)  and  79%  bone marrow  cells of young adult 
mice  were positive  for  both  CC11  and  CB5  antigens,  but  cells from  thymus, 
lymph node, heart, and kidney were negative. The molecule recognized by both 
antibodies has an Mr of 50,000-70,000,  a  pI of 5.7-6.2,  and carries heteroge- 
neous N-linked  glycans of high  11,/,-. Both CC11  and  CB5 specifically inhibited 
the growth of clones supported by rIL-3.  Neither antibody affected the action 
of IL-I, IL-2, or B cell maturation  factor; the proliferative responses of spleno- 
cytes  to  Con  A,  PWM,  and  LPS;  nor  the  maturation  of spleen  B  cells  into 
antibody-secreting  cells  stimulated  by  LPS.  rIL-3  specifically  modulated  the 
expression of the CC 11/CB5 glycoprotein on the cell membrane of IL-3-depend- 
ent clones. Finally, freshly isolated bone marrow cells that have the CC11/CB5 
glycoprotein  on  the  cell  membrane  proliferated  in  response  to  IL-3,  whereas 
cells that lack this molecule did not. We suggest that CC11 and CB5 react against 
receptors for mouse IL-3. 
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